This interactive educational activity will provide an update on the latest research on the development of new therapies for patients with breast cancer that is difficult to treat due to challenging phenotypes or resistance to or intolerable toxicity from standard therapies. Through discussion of patient scenarios and clinically relevant issues, experts will also offer guidance on how to integrate this information into everyday practice.

Upon completion of this activity, participants should be better able to:

• Critically evaluate the latest data on treatment options for patients with chemotherapy-refractory/resistant or triple-negative advanced breast cancer populations, and consider the clinical implications of these data in the context of the current standard of care
• Apply the most up-to-date concepts regarding the optimization of treatment using established and newer agents in defined clinical scenarios in advanced difficult-to-treat breast cancer based on examples of challenging case studies

This activity has been designed to meet the educational needs of US medical oncologists and other clinicians involved in managing patients with breast cancer.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media:

Internet

Release and Expiration Dates:

December 18, 2009 - December 17, 2010

Time to Complete:

30 minutes

Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Hope S. Rugo, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Abbott Laboratories; Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Novartis Oncology; and Pfizer Inc goes to the University of California, San Francisco.
Speakers Bureau participant with AstraZeneca, Ltd.; Eli Lilly and Company; and Genomic Health, Inc.

William J. Gradishar, MD
Professor of Medicine
Director, Breast Medical Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
The Feinberg School of Medicine
Chicago, Illinois

William J. Gradishar, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Abraxis Oncology; Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; and sanofi-aventis.

Jeffrey B. Smerage, MD, PhD
Clinical Assistant Professor
Department of Internal Medicine
Division of Hematology/Oncology
University of Michigan Medical School
Ann Arbor, Michigan

Jeffrey B. Smerage, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Genentech, Inc.; Genomic Health, Inc.; and Immunicon Corporation.
Speakers Bureau participant with Lilly Research Laboratories.

Mr. Pierre Lavalard, MBA
Associate Director
Office of CME
Department of Medical Education
University of Michigan Medical School
Ann Arbor, Michigan

Mr. Pierre Lavalard, MBA, currently has no financial interests/relationships or affiliations in relation to this activity.

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education, Inc.

Kadrin Wilfong, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Michigan Medical School and PVI, PeerView Institute for Medical Education. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

The University of Michigan Medical School designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is supported by an educational grant from